Also trades as: AMYT.L (LSE) · $vol 0M
AMYT NASDAQ
Amryt Pharma plc
1W: +0.0%
1M: +0.7%
3M: +0.2%
1Y: +94.4%
$14.70
Last traded 2023-04-21 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
By Geography
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$223M
+21.9% ▲
5Y CAGR: +174.8%
Gross Profit
$116M
+83.1% ▲
5Y CAGR: +170.5%
Operating Income
-$22M
+52.4% ▲
Net Income
-$18M
+82.6% ▲
EPS (Diluted)
$-0.37
+87.3% ▲
EBITDA
$77M
+3078.8% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $15M | $17M | $58M | $183M | $223M |
| YoY Growth | +978.8% | +7.9% | +251.5% | +214.2% | +21.9% |
| Cost of Revenue | $6M | $6M | $42M | $119M | $106M |
| Gross Profit | $9M | $10M | $16M | $64M | $116M |
| Gross Margin | 58.0% | 63.3% | 27.7% | 34.8% | 52.3% |
| R&D Expenses | $13M | $10M | $16M | $28M | $38M |
| SG&A Expenses | $13M | $18M | $36M | $77M | $100M |
| Operating Expenses | $26M | $28M | $52M | $109M | $138M |
| Operating Income | -$17M | -$17M | -$36M | -$45M | -$22M |
| Operating Margin | -111.2% | -105.5% | -62.0% | -24.9% | -9.7% |
| Interest Expense | $990K | $2M | $8M | $20M | $28M |
| Income Before Tax | -$31M | -$29M | -$67M | -$106M | -$30M |
| Tax Expense | $14M | $41K | -$1M | -$1M | -$12M |
| Net Income | -$46M | -$29M | -$66M | -$105M | -$18M |
| Net Margin | -297.9% | -178.3% | -112.8% | -57.2% | -8.2% |
| EPS (Diluted) | $-6.14 | $-3.22 | $-4.32 | $-2.92 | $-0.37 |
| EBITDA | -$17M | -$17M | -$37M | -$22M | $77M |
| Shares Outstanding | 7M | 9M | 15M | 36M | 49M |